On June 3, 2021, Stablix Therapeutics announced a $63 million Series A financing. The funding round was led by founding investor Versant Ventures along with NEA, Cormorant, Euclidean Capital, and Alexandria Real Estate Equities. Wilson Sonsini Goodrich & Rosati advised Versant Ventures and NEA in the financing.

Stablix, a biotechnology company pioneering in the field of Targeted Protein Stabilization, initially is leveraging its proprietary platform to develop programs to treat rare diseases, cancer, and immunological disorders. The company plans to use the proceeds from the Series A financing to expand its platform and advance a portfolio of protein stabilizers towards the clinic. The company also has established a lab facility in New York City, where it is building a research team.

The Wilson Sonsini team advising Versant and NEA includes partner Dan Koeppen and associate Meg Burton.

Please see the company’s press release for more information.